81 related articles for article (PubMed ID: 26385387)
1. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Fabarius A; Kalmanti L; Dietz CT; Lauseker M; Rinaldetti S; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Hanfstein B; Seifarth W; Hänel M; Köhne CH; Lindemann HW; Berdel WE; Staib P; Müller MC; Proetel U; Balleisen L; Goebeler ME; Dengler J; Falge C; Kanz L; Burchert A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Brümmendorf TH; Edinger M; Hofmann WK; Pfirrmann M; Hasford J; Krause S; Hochhaus A; Saußele S; Hehlmann R;
Ann Hematol; 2015 Dec; 94(12):2015-24. PubMed ID: 26385387
[TBL] [Abstract][Full Text] [Related]
2. Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
Claudiani S; Chee L; Fernando F; Brown L; Achandira UM; Khan A; Rothwell K; Hayden C; Koutsavlis I; Hannah G; Innes A; Apperley JF; Milojkovic D
Am J Hematol; 2024 Jun; 99(6):1172-1174. PubMed ID: 38436141
[TBL] [Abstract][Full Text] [Related]
3. The cytogenetic scenario of chronic myeloid leukemia.
Mitelman F
Leuk Lymphoma; 1993; 11 Suppl 1():11-5. PubMed ID: 8251885
[TBL] [Abstract][Full Text] [Related]
4. The concept of treatment-free remission in chronic myeloid leukemia.
Saußele S; Richter J; Hochhaus A; Mahon FX
Leukemia; 2016 Aug; 30(8):1638-47. PubMed ID: 27133824
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
Alhuraiji A; Kantarjian H; Boddu P; Ravandi F; Borthakur G; DiNardo C; Daver N; Kadia T; Pemmaraju N; Pierce S; Garcia-Manero G; Wierda W; Verstovsek S; Jabbour E; Cortes J
Am J Hematol; 2018 Jan; 93(1):84-90. PubMed ID: 29027261
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.
Thompson PA; Kantarjian HM; Cortes JE
Mayo Clin Proc; 2015 Oct; 90(10):1440-54. PubMed ID: 26434969
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
Gratwohl A; Pfirrmann M; Zander A; Kröger N; Beelen D; Novotny J; Nerl C; Scheid C; Spiekermann K; Mayer J; Sayer HG; Falge C; Bunjes D; Döhner H; Ganser A; Schmidt-Wolf I; Schwerdtfeger R; Baurmann H; Kuse R; Schmitz N; Wehmeier A; Fischer JT; Ho AD; Wilhelm M; Goebeler ME; Lindemann HW; Bormann M; Hertenstein B; Schlimok G; Baerlocher GM; Aul C; Pfreundschuh M; Fabian M; Staib P; Edinger M; Schatz M; Fauser A; Arnold R; Kindler T; Wulf G; Rosselet A; Hellmann A; Schäfer E; Prümmer O; Schenk M; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Büsche G; Haferlach C; Schnittger S; Müller MC; Reiter A; Berger U; Saußele S; Hochhaus A; Hehlmann R; ;
Leukemia; 2016 Mar; 30(3):562-9. PubMed ID: 26464170
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays.
Bennour A; Saad A; Sennana H
Crit Rev Oncol Hematol; 2016 Jan; 97():263-74. PubMed ID: 26412717
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia: First-line drug of choice.
Jabbour E
Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
[TBL] [Abstract][Full Text] [Related]
12. Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions.
Volkert S; Haferlach T; Holzwarth J; Zenger M; Kern W; Staller M; Nagata Y; Yoshida K; Ogawa S; Schnittger S; Haferlach C
Leukemia; 2016 Jan; 30(1):257-60. PubMed ID: 26392226
[No Abstract] [Full Text] [Related]
13. Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia.
Ziai JM; Siddon AJ;
Am J Clin Pathol; 2015 Oct; 144(4):539-54. PubMed ID: 26386075
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
[TBL] [Abstract][Full Text] [Related]
15. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.
Gong Z; Medeiros LJ; Cortes JE; Chen Z; Zheng L; Li Y; Bai S; Lin P; Miranda RN; Jorgensen JL; McDonnell TJ; Wang W; Kantarjian HM; Hu S
Blood Adv; 2017 Dec; 1(26):2541-2552. PubMed ID: 29296906
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre PD; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Lustgarten S; Rivera VM; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes TP; Shah NP; Kantarjian HM
Blood; 2018 Jul; 132(4):393-404. PubMed ID: 29567798
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
19. High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R; Voskanyan A; Lauseker M; Pfirrmann M; Kalmanti L; Rinaldetti S; Kohlbrenner K; Haferlach C; Schlegelberger B; Fabarius A; Seifarth W; Spieß B; Wuchter P; Krause S; Kolb HJ; Neubauer A; Hossfeld DK; Nerl C; Gratwohl A; Baerlocher GM; Burchert A; Brümmendorf TH; Hasford J; Hochhaus A; Saußele S; Baccarani M;
Leukemia; 2020 Aug; 34(8):2074-2086. PubMed ID: 32382082
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
